Evidence map›Paper›PMID 24743560›Full record

Observational studyThorax2014

Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?

Michelle T Harrison, Philip Short, Peter A Williamson, Aran Singanayagam, James D Chalmers, Stuart Schembri

Open access · bronzeAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Thorax, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Urine and Plasma Markers of Platelet Activation and Respiratory Symptoms in COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Platelets: a potential role in chronic respiratory diseases?European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  19. Platelets in Bronchiectasis: Player or Spectator?Annals of the American Thoracic Society · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Michelle T HarrisonTayside Respiratory Research Group, Ninewells Hospital and Medical School, Dundee, UK.
Philip ShortTayside Respiratory Research Group, Ninewells Hospital and Medical School, Dundee, UK University of Dundee, Dundee, UK.
Peter A WilliamsonTayside Respiratory Research Group, Ninewells Hospital and Medical School, Dundee, UK Perth Royal Infirmary, Perth, UK.
Aran SinganayagamImperial College London, London, UK.
James D ChalmersTayside Respiratory Research Group, Ninewells Hospital and Medical School, Dundee, UK University of Dundee, Dundee, UK.
Stuart SchembriTayside Respiratory Research Group, Ninewells Hospital and Medical School, Dundee, UK.
Ninewells Hospital · GBUniversity of Dundee · GBImperial College London · GBPerth Royal Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvidence suggests that platelets play a significant role in inflammation in addition to their role in thrombosis. Systemic inflammation is linked to poor short and long term outcomes in COPD. Increased platelet activation has been reported in acute exacerbations of COPD (AECOPD). We investigated whether thrombocytosis is independently associated with poor outcomes following AECOPD.

methodsAn observational cohort study of patients hospitalised with AECOPD was performed. Patients were >40 years with spirometry confirmed COPD admitted between 2009 and 2011. Platelet count was recorded on admission. The primary outcome was 1-year all-cause mortality. Secondary outcomes included inhospital mortality and cardiovascular events. Analyses were conducted using logistic regression after adjustment for confounding variables.

results1343 patients (49% male) were included. Median age was 72 years (IQR 63-79 years). 157 (11.7%) had thrombocytosis. Thrombocytosis was associated with both 1-year mortality and inhospital mortality; OR 1.53 (95% CI 1.03 to 2.29, p=0.030) and OR 2.37 (95% CI 1.29 to 4.34, p=0.005), respectively. Cardiovascular hospitalisation was not significantly increased (OR 1.13 (95% CI 0.73 to 1.76, p=0.600)) in patients with thrombocytosis. Aspirin or clopidogrel treatment correlated with a reduction in 1-year mortality (OR 0.63 (95% CI 0.47 to 0.85, p=0.003)) but not inhospital mortality (OR 0.69 (95% CI 0.41 to 1.11, p=0.124)).

conclusionsAfter adjustment for confounders thrombocytosis was associated with increased 1-year mortality after exacerbation of COPD. Antiplatelet therapy was associated with significantly lower 1-year mortality and may have a protective role to play in patients with AECOPD.

Indexed as

AgedAspirinClopidogrelFemaleHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPulmonary Disease, Chronic ObstructiveSpirometryThrombocytosisTiclopidineAspirinClopidogrelPlatelet Aggregation InhibitorsTiclopidine

Identifiers

PMID24743560
OpenAlexW2148364073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.